27.98  0.47 (1.71%)		06-04 11:58
Open: 27.5 High: 28.09 Volume: 2,385		Pre. Close: 27.51 Low: 27.5 Market Cap: 1,844(M)

Short term
Mid term
Targets	6-month :	34.49	1-year :	40.29
Resists	First :	29.53	Second :	34.49
Pivot price	28.62
Supports	First :	27.91	Second :	26.92
MAs	MA(5) :	29.06	MA(20) :	28.4
	MA(100) :	30.13	MA(250) :	31.44
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	85.9	D(3) :	85
RSI	RSI(14): 62.4
52-week	High :	37.77	Low :	26.42

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GLPG ] has closed below upper band by 0.5%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	29.55 - 29.7	29.7 - 29.84
Low:	28.43 - 28.58	28.58 - 28.73
Close:	29.26 - 29.5	29.5 - 29.74

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Tue, 21 Jul 2026
GLPG Q1 2026 Earnings: Significant EPS Beat Driven by Cost Discipline and Pipeline Progress - Revenue Inflection Point - careplusvn.com

Thu, 16 Jul 2026
Galapagos NV (GLPG) Q1 2026 Earnings: EPS Surprise Defies Analyst Expectations - Dividend Earnings Report - dars.gov.et

Thu, 16 Jul 2026
GLPG Q1 2026 Earnings: Stunning EPS Surprise Driven by Sharp Cost Discipline and Non-Operational Gains - EBITDA Estimate Trend - careplusvn.com

Fri, 24 Apr 2026
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1 - finance.yahoo.com

Sat, 04 Apr 2026
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - finance.yahoo.com

Thu, 26 Mar 2026
Galapagos NV (GLPG) Releases Q4 2025 Earnings: Revenue and Gross-Profit Surge, But Operating and Net Losses Persist - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	66 (M)
Shares Float	45 (M)
Held by Insiders	25.3 (%)
Held by Institutions	22.3 (%)
Shares Short	1,370 (K)
Shares Short P.Month	911 (K)

EPS	8.71
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.9
Profit Margin	46.8 %
Operating Margin	-983 %
Return on Assets (ttm)	10.6 %
Return on Equity (ttm)	16.2 %
Qtrly Rev. Growth	-91.5 %
Gross Profit (p.s.)	8.55
Sales Per Share	15.78
EBITDA (p.s.)	10.06
Qtrly Earnings Growth	0 %
Operating Cash Flow	-302 (M)
Levered Free Cash Flow	211 (M)

PE Ratio	3.38
PEG Ratio	0
Price to Book value	10.17
Price to Sales	1.86
Price to Cash Flow	-6.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.